Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Instituto Butantan is active in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions. These actions are distributed across 3 distinct examiners, which means each pending application is being reviewed by a different individual. This variety of examiners can lead to different prosecution experiences for each matter in the portfolio.
The portfolio's work is spread across 2 distinct art units. This indicates that the company's biotechnology innovations are diverse enough to be categorized into two different technical areas by the patent office. GRASER, JENNIFER E is the busiest examiner for the portfolio, with 1 pending office action. This examiner's workload is one of three equal parts of the total pending actions.
The workload is evenly balanced, as the busiest examiner is responsible for 1 of the 3 total pending actions. This distribution ensures that no single examiner has a dominant influence on the portfolio's progress. Practitioners should be prepared to navigate the requirements of 2 distinct art units and the individual styles of three separate examiners. This structure requires a flexible strategy to manage the different technical and examiner-specific demands.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRASER, JENNIFER E | 1 | 76.7% | +23.4% |
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
| JADHAO, SAMADHAN JAISING | 1 | 46.9% | +46.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837804 | COMPOSITIONS COMPRISING RECOMBINANT STRAINS OF MYCOBACTERIUM, USES THEREOF AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF CANCER | GRASER, JENNIFER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782899 | PROCESS FOR PRODUCING A PROPHYLACTIC AND THERAPEUTIC DNA IMMUNOLOGICAL COMPOSITION FOR HPV AND CANCERS ASSOCIATED WITH THE VIRUS, HYBRID PROTEIN, EXPRESSION VECTOR, IMMUNOLOGICAL COMPOSITION AND USES THEREOF | JADHAO, SAMADHAN JAISING | 25d overdue |
| 18837804 | COMPOSITIONS COMPRISING RECOMBINANT STRAINS OF MYCOBACTERIUM, USES THEREOF AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF CANCER | GRASER, JENNIFER E | — |
| 18003258 | PROCESS FOR OBTAINING ANTIGEN-PRESENTING VESICLES (APV) THAT ENABLES THE COUPLING OF ONE OR MORE ANTIGENS | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837804 | COMPOSITIONS COMPRISING RECOMBINANT STRAINS OF MYCOBACTERIUM, USES THEREOF AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF CANCER | GRASER, JENNIFER E | — | §103§112 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18003258 | PROCESS FOR OBTAINING ANTIGEN-PRESENTING VESICLES (APV) THAT ENABLES THE COUPLING OF ONE OR MORE ANTIGENS | DEBERRY, REGINA M | 1647 | §112 | Final Rejection | — | Pending | Dec 23, 2022 |
| 17782899 | PROCESS FOR PRODUCING A PROPHYLACTIC AND THERAPEUTIC DNA IMMUNOLOGICAL COMPOSITION FOR HPV AND CANCERS ASSOCIATED WITH THE VIRUS, HYBRID PROTEIN, EXPRESSION VECTOR, IMMUNOLOGICAL COMPOSITION AND USES THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §112 | Final Rejection | 25d overdue | Pending | Jun 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial